View More Recent Stories
-
BMO Capital Sees Attractive Entry Point in Ionis (IONS) Amid Sell-Off; Says NEURO-TTR Study Unaffected By Hold
-
BMO Capital Starts Ionis Pharmaceuticals (IONS) at Outperform
